Mood Changes
Also known as: Mood Lability · Irritability · Low Mood
New-onset mood lability, irritability, or low mood in midlife is frequently hormonally driven and not adequately addressed by mental-health treatment alone. Estradiol, progesterone, testosterone, thyroid, and inflammation are common substrates.
What you need to know
Mood is downstream of estradiol stability (women), testosterone (both sexes), thyroid function, B12, vitamin D, and inflammatory tone. Perimenopausal mood changes in particular respond poorly to SSRI monotherapy because the underlying hormonal variability remains. A complete evaluation reviews biomarkers in parallel with mental-health context. Optimization-medicine framing does not replace psychiatric care — it complements it by addressing the physiological substrate.
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Underlying conditions
- Perimenopause
- Menopause
- Low Testosterone
- Hypothyroidism
- Hashimoto's Thyroiditis
- Hyperthyroidism
- Graves' Disease
- Polycystic Ovary Syndrome (PCOS)
- Estrogen Dominance
- Low Progesterone
- Premenstrual Syndrome (PMS)
- Vitamin D Deficiency
- Obstructive Sleep Apnea
- Premature Ovarian Insufficiency
- Hyperprolactinemia
- Subclinical Hypothyroidism
- Endometriosis
- Premature Ejaculation
- Female Pattern Hair Loss
- Hormonal Acne
- Depression
- Chronic Insomnia
- Premenstrual Dysphoric Disorder
Diagnostic biomarkers
Bring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.